On December 3, 2020 McKesson Corporation reported the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer (Press release, McKesson, DEC 3, 2020, View Source [SID1234572141]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Ontada reflects McKesson’s continued commitment and investment in the oncology community," said Brian Tyler, chief executive officer, McKesson. "As one of the largest healthcare companies, McKesson is at the center of care delivery, which provides a unique perspective on the complexities of cancer care and the growing needs among providers and life sciences companies. With the launch of Ontada, we can now build upon our differentiated assets in oncology and deliver innovative solutions that help improve patient outcomes."
Building on McKesson’s long history in community oncology, Ontada combines its real-world data and research capabilities with a leading suite of technologies for oncology clinicians – including the iKnowMed℠ electronic health record system and Clear Value Plus℠ regimen support tool – as well as a connection to a national community oncology network to transform the fight against cancer.
Ontada is uniquely positioned to advance cancer care by enabling deep collaboration between life sciences companies and oncology providers. Its team of data scientists and oncology experts help life sciences companies leverage evidence-based data and insights to accelerate innovation and improve cancer therapy, while empowering providers to deliver the best care and improved outcomes for patients. Ontada will provide a number of real clinical benefits to enable life sciences companies to help bring breakthrough oncology products to market sooner and better support the entire patient journey.
Through its deep connections to oncology practices, Ontada can help expand the reach of therapies with engagement and education opportunities with physicians. The benefits that Ontada can offer to providers are further enhanced through its strong relationship with McKesson’s The US Oncology Network, as well as other community oncology practices.
"At The US Oncology Network, we collaborate with practices to leverage evidence-driven care to deliver better patient outcomes," said Michael Seiden, M.D., Ph.D., president, The US Oncology Network. "We’re thrilled to have Ontada as a technology partner who shares our vision and will provide us with the tools and insights we need to put patients first."